Kyverna Therapeutics Statistics
Total Valuation
KYTX has a market cap or net worth of $536.24 million. The enterprise value is $301.73 million.
Important Dates
The next estimated earnings date is Tuesday, May 12, 2026, after market close.
| Earnings Date | May 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
KYTX has 60.46 million shares outstanding. The number of shares has increased by 15.46% in one year.
| Current Share Class | 60.46M |
| Shares Outstanding | 60.46M |
| Shares Change (YoY) | +15.46% |
| Shares Change (QoQ) | +8.62% |
| Owned by Insiders (%) | 1.75% |
| Owned by Institutions (%) | 38.45% |
| Float | 35.12M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 2.28 |
| P/TBV Ratio | 2.38 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.75, with a Debt / Equity ratio of 0.12.
| Current Ratio | 7.75 |
| Quick Ratio | 7.65 |
| Debt / Equity | 0.12 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -347.29 |
Financial Efficiency
Return on equity (ROE) is -64.67% and return on invested capital (ROIC) is -39.60%.
| Return on Equity (ROE) | -64.67% |
| Return on Assets (ROA) | -35.47% |
| Return on Invested Capital (ROIC) | -39.60% |
| Return on Capital Employed (ROCE) | -65.99% |
| Weighted Average Cost of Capital (WACC) | 17.90% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.25M |
| Employee Count | 129 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +347.98% in the last 52 weeks. The beta is 2.64, so KYTX's price volatility has been higher than the market average.
| Beta (5Y) | 2.64 |
| 52-Week Price Change | +347.98% |
| 50-Day Moving Average | 8.28 |
| 200-Day Moving Average | 6.43 |
| Relative Strength Index (RSI) | 57.12 |
| Average Volume (20 Days) | 702,154 |
Short Selling Information
The latest short interest is 4.21 million, so 6.96% of the outstanding shares have been sold short.
| Short Interest | 4.21M |
| Short Previous Month | 4.19M |
| Short % of Shares Out | 6.96% |
| Short % of Float | 11.97% |
| Short Ratio (days to cover) | 7.19 |
Income Statement
| Revenue | n/a |
| Gross Profit | -133.72M |
| Operating Income | -169.83M |
| Pretax Income | -161.31M |
| Net Income | -161.31M |
| EBITDA | -168.03M |
| EBIT | -169.83M |
| Earnings Per Share (EPS) | -$3.64 |
Full Income StatementBalance Sheet
The company has $279.25 million in cash and $29.03 million in debt, with a net cash position of $250.22 million or $4.14 per share.
| Cash & Cash Equivalents | 279.25M |
| Total Debt | 29.03M |
| Net Cash | 250.22M |
| Net Cash Per Share | $4.14 |
| Equity (Book Value) | 232.28M |
| Book Value Per Share | 3.85 |
| Working Capital | 246.47M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$153.71 million and capital expenditures -$5,000, giving a free cash flow of -$153.72 million.
| Operating Cash Flow | -153.71M |
| Capital Expenditures | -5,000 |
| Depreciation & Amortization | 1.80M |
| Net Borrowing | 23.89M |
| Free Cash Flow | -153.72M |
| FCF Per Share | -$2.54 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
KYTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -15.46% |
| Shareholder Yield | -15.46% |
| Earnings Yield | -29.22% |
| FCF Yield | -27.85% |
Analyst Forecast
The average price target for KYTX is $20.75, which is 133.94% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $20.75 |
| Price Target Difference | 133.94% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | -18.00% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
